Troglitazone was a peroxisome proliferator‐activated receptor γ (PPARγ) agonist and insulin sensitizer, mainly used in the treatment of type 2 diabetes mellitus and insulin resistance. The gene discussed is PPARG; the disease is diabetes mellitus.